Search results for "IL-5"

showing 5 items of 5 documents

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

2021

Abstract Background and aims Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of workin…

OR Odds RatioPediatricsSevere asthmaExacerbationAnti IL-5; Comorbidities; Mepolizumab; OCS; Pharmacoeconomics; Severe asthmagastroesophageal reflux diseaseSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOICS inhaled corticosteroidRate ratioOCS Oral Corticosteroidslaw.inventionComorbiditiesLAMA long acting muscarinic antagonist0302 clinical medicineRandomized controlled trialfractional nitric oxideInterquartile rangelawlong acting beta 2 agonistOdds RatioImmunology and AllergyRR Rate Ratio030223 otorhinolaryngologyPharmacoeconomicLOS Length of stayLOSIQRLAMAMEP MepolizumabORCISD Standard DeviationMEPPharmacoeconomicsACT Asthma Control TestComorbiditieCI Confidence Intervalsmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyinterquartile rangelong acting muscarinic antagonistImmunologyLABALABA long acting beta 2 agonistComorbidities Mepolizumab OCS Pharmacoeconomics Severe asthma Anti IL-5RRArticleRate Ratiochronic obstructive pulmonary disease03 medical and health sciencesPharmacoeconomicsOCS Oral CorticosteroidAsthma Control TestConfidence IntervalsFeNO fractional nitric oxideRCTs Randomized Controlled TrialmedicineCOPDGERD gastroesophageal reflux diseaseFeNOIQR interquartile rangeMepolizumabSDAsthmaRCTsOral Corticosteroidsbusiness.industryGERDmedicine.diseaseICS inhaled corticosteroidsACTComorbidityRandomized Controlled TrialsCI Confidence IntervalRCTs Randomized Controlled TrialsOCSCOPD chronic obstructive pulmonary disease030228 respiratory systemICSStandard DeviationLength of stayAnti IL-5inhaled corticosteroidslcsh:RC581-607businessMepolizumab
researchProduct

Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion

2019

We report about a case of a compassionate off-label use of the anti-interleukin-5-agent mepolizumab in a ventilated patient with life-threatening asthma attack in eosinophilic asthma. The patient suffered from severe eosinophilic asthma and was transmitted to our hospital with an asthma attack and a life-threatening respiratory state under ventilation. Since high dose steroids had not yielded a sufficient respiratory improvement mepolizumab was administered subcutaneously. After administration of mepolizumab respiratory state and ventilation parameter improved significantly. Two days after administration the patient was weaned could be extubated 8 days later and recovered completely from th…

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyExacerbationAnti-IL-5-therapyCase Report03 medical and health sciences0302 clinical medicineEosinophiliamedicineEosinophiliaIntensive care medicineRespiratory systemInterleukin 5Asthmalcsh:RC705-779business.industryExacerbationlcsh:Diseases of the respiratory systemmedicine.diseaseAsthmarespiratory tract diseasesClinical trial030228 respiratory system030220 oncology & carcinogenesisBreathingmedicine.symptombusinessMepolizumabmedicine.drugRespiratory Medicine Case Reports
researchProduct

Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma: Real-life evaluation correlated with allergic and non-aller…

2021

Corrado Pelaia,1 Claudia Crimi,2 Alida Benfante,3 Maria Filomena Caiaffa,4 Cecilia Calabrese,5 Giovanna Elisiana Carpagnano,6 Domenico Ciotta Jnr,7 Maria D’Amato,8 Luigi Macchia,9 Santi Nolasco,2 Girolamo Pelaia,1 Simona Pellegrino,7 Nicola Scichilone,3 Giulia Scioscia,10 Giuseppe Spadaro,11 Giuseppe Valenti,12 Alessandro Vatrella,7 Nunzio Crimi2 1Department of Health Sciences, University “Magna Graecia” of Catanzaro, Catanzaro, Italy; 2Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; 3Department of Biomedicine and Internal and Specialistic Medicine, University of Palermo, Palermo, Italy; 4Allergology and Clinical Immunol…

Pulmonary and Respiratory Medicinelcsh:Immunologic diseases. Allergymedicine.medical_specialtyVital capacityallergic and non allergic phenotypesAsthma exacerbationSettore MED/10 - Malattie Dell'Apparato Respiratoriobenralizumab.FEV1/FVC ratiochemistry.chemical_compoundPrednisoneInternal medicineIL-5 receptorJournal of Asthma and AllergyImmunology and AllergyMedicineClinical significanceAsthmaOriginal ResearchAllergic and non-allergic phenotypebusiness.industrySevere eosinophilic asthmaTherapeutic effectBenralizumabmedicine.diseaseBenralizumabchemistryasthma exacerbationsExhaled nitric oxideallergic and non-allergic phenotypesbusinesslcsh:RC581-607Allergic and non-allergic phenotypesAsthma exacerbations Benralizumab IL-5 receptor Severe eosinophilic asthmaAllergic and non-allergic phenotypes; Asthma exacerbations; Benralizumab; IL-5 receptor; Severe eosinophilic asthmamedicine.drug
researchProduct

Onset of Effect, Changes in Airflow Obstruction and Lung Volume, and Health-Related Quality of Life Improvements with Benralizumab for Patients with …

2020

Reynold A Panettieri Jr,1 Tobias Welte,2 Kartik V Shenoy,3 Stephanie Korn,4 Margret Jandl,5 Edward M Kerwin,6 Rosa Feijoo,7 Peter Barker,8 Richard F Olsson,9 Ubaldo J Martin8 On behalf of the SOLANA Study Investigators1Pulmonary, Allergy and Critical Care Division, University of Pennsylvania, Philadelphia, PA, USA; 2Department of Respiratory Medicine, Member of the German Center of Lung Research, Medizinische Hochschule Hannover, Hannover, Germany; 3Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA; 4Pulmonary Department, Universitätsmedizin Mainz, Langenbeckstr, Mainz, Germany; 5Hamburger Institut Für Th…

Pulmonary and Respiratory Medicinesevere asthmamedicine.medical_specialtybenralizumabPlacebolaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicineClinical endpointJournal of Asthma and AllergyImmunology and AllergyMedicinePlethysmographLung volumesOriginal Researchbusiness.industryBenralizumabanti–IL-5RαConfidence intervalchemistryAsthma Control Questionnairerandomized controlled trialinterleukin-5businesseosinophilicJournal of Asthma and Allergy
researchProduct

Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study

2021

Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) affects around 60% of patients with severe eosinophilic asthma (SEA). Benralizumab was recently approved for SEA add-on treatment. Objective: To assess the real-world effectiveness of benralizumab in SEA with or without CRSwNP. Methods: We conducted a multicenter observational study, including patients with SEA treated with benralizumab for 24 weeks in 12 Italian specialized facilities. Asthma exacerbations, Asthma Control Test (ACT), lung function, oral corticosteroid (OCS) dosage, and eosinophil and basophil count in peripheral blood were recorded at baseline and after 4, 12, and 24 weeks. The 22-item Sino-Nasal Outcome Test (S…

Severe asthmaVital capacitymedicine.medical_specialtymedicine.drug_classSettore MED/10 - Malattie Dell'Apparato RespiratorioAntibodies Monoclonal HumanizedFEV1/FVC ratiochemistry.chemical_compoundNasal PolypsInternal medicinemedicineHumansImmunology and AllergyNasal polypsAnti-Asthmatic AgentsIL-5Nasal polypbusiness.industryMinimal clinically important differenceBenralizumabFunctional endoscopic sinus surgeryrespiratory systemEosinophilBenralizumabmedicine.diseaseAsthmaChronic rhinosinusitismedicine.anatomical_structureReal-worldchemistryChronic rhinosinusitiCorticosteroidbusinessHumanThe Journal of Allergy and Clinical Immunology: In Practice
researchProduct